Dyne Therapeutics (DYN) Enterprise Value (2020 - 2026)

Dyne Therapeutics (DYN) has reported Enterprise Value for 8 consecutive years, with -$898.5 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Enterprise Value fell 50.49% year-over-year to -$898.5 million; the TTM figure through Jun 2026 stood at -$898.5 million (down 50.49% YoY), while the FY2025 annual figure was -$1.1 billion, down 72.91% from the prior year.
• Enterprise Value improved to -$898.5 million in Q2 2026 per DYN's latest filing, from -$972.2 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$123.1 million in Q4 2023 and bottomed at -$1.1 billion in Q4 2025.
• Historically, Enterprise Value has averaged -$527.3 million across 5 years, with a median of -$525.3 million in 2024.
• Annual changes were most pronounced in 2023 — Enterprise Value jumped 51.92% — and 2024, when it sank 421.74%.
• Dyne Therapeutics' Enterprise Value stood at -$256.0 million in 2022, then surged by 51.92% to -$123.1 million in 2023, then tumbled by 421.74% to -$642.3 million in 2024, then sank by 72.91% to -$1.1 billion in 2025, then increased by 19.1% to -$898.5 million in 2026.
• Business Quant data shows DYN's Enterprise Value at -$898.5 million in Q2 2026, -$972.2 million in Q1 2026, and -$1.1 billion in Q4 2025.